

# CONTENTS

---

## 1 MOLECULAR BIOLOGY OF CANCER, 1

Jesse D. Martinez  
Michele Taylor Parker  
Kimberly E. Fultz  
Natalia A. Ignatenko  
Eugene W. Gerner  
*Departments of Radiation Oncology/  
Cancer Biology Section  
Molecular and Cellular Biology  
Biochemistry and Molecular  
Biophysics  
Cancer Biology Graduate Program  
The University of Arizona  
Tuscon, Arizona*

## 2 SYNTHETIC DNA-TARGETED CHEMOTHERAPEUTIC AGENTS AND RELATED TUMOR- ACTIVATED PRODRUGS, 51

William A. Denny  
*Auckland Cancer Society Research  
Centre  
Faculty of Medical and Health  
Sciences  
The University of Auckland  
Auckland, New Zealand*

## 3 ANTITUMOR NATURAL PRODUCTS, 107

Lester A. Mitscher  
Apurba Dutta  
*Department of Medicinal Chemistry  
Kansas University  
Lawrence, Kansas*

## 4 RADIOSENSITIZERS AND RADIOPROTECTIVE AGENTS, 151

Edward A. Bump  
*DRAXIMAGE Inc.  
Kirkland, Quebec, Canada*

Stephen J. Hoffman  
*Allos Therapeutics, Inc.  
Westminster, Colorado*

William O. Foye  
*Massachusetts College of Pharmacy  
and Health Sciences  
Boston, Massachusetts*

## 5 SYNTHETIC ANTIANGIOGENIC AGENTS, 215

Orest W. Blaschuk  
*Mc Gill University, Royal Victoria  
Hospital  
Montreal, Quebec, Canada*

J. Matthew Symonds  
*Adherex Technologies Inc.  
Ottawa, Ontario, Canada*

**6 FUTURE STRATEGIES IN IMMUNOTHERAPY, 223**

Douglas F. Lake  
Sara O. Dionne  
*University of Arizona Cancer Center  
Tucson, Arizona*

**7 SELECTIVE TOXICITY, 249**

John H. Block  
*College of Pharmacy  
Oregon State University  
Corvallis, Oregon*

**8 DRUG RESISTANCE IN CANCER CHEMOTHERAPY, 281**

Amelia M. Wall  
*Division of Clinical Pharmacology  
and Therapeutics  
Children's Hospital of Philadelphia  
Cancer Pharmacology Institute  
University of Pennsylvania  
Philadelphia, Pennsylvania*

**9 ANTIVIRAL AGENTS, DNA, 293**

Tim Middleton  
Todd Rockway  
*Abbott Laboratories  
Abbott Park, Illinois*

**10 ANTIVIRAL AGENTS, RNA VIRUSES (OTHER THAN HIV), AND ORTHOPOXVIRUSES, 359**

Christopher Tseng  
Catherine Laughlin  
*NIAID  
National Institutes of Health  
Bethesda, Maryland*

**11 RATIONALE OF DESIGN OF ANTI-HIV DRUGS, 457**

Ahmed S. Mehanna  
*Massachusetts College of Pharmacy  
and Health Sciences  
Department of Pharmaceutical  
Sciences  
School of Pharmacy  
Boston, Massachusetts*

**12 ORGAN TRANSPLANT DRUGS, 485**

Bijoy Kundu  
*Medicinal Chemistry Division  
Central Drug Research Institute  
Lucknow, India*

**13 SYNTHETIC ANTIBACTERIAL AGENTS, 537**

Nitya Anand  
*B-62, Nirala Nagar,  
Lucknow, India*

William A. Remers  
*University of Arizona  
College of Pharmacy  
Tucson, Arizona*

**14  $\beta$ -LACTAM ANTIBIOTICS, 607**

Daniele Andreotti  
Stefano Biondi  
Enza Di Modugno  
*GlaxoSmithKline Research Center  
Verona, Italy*

**15 TETRACYCLINE, AMINOGLYCOSIDE, MACROLIDE, AND MISCELLANEOUS ANTIBIOTICS, 737**

Gerard D. Wright  
*Antimicrobial Research Centre  
Department of Biochemistry  
McMaster University  
Hamilton, Ontario, Canada*

Daniel T. W. Chu  
*Chiron Corporation  
Emeryville, California*

16 ANTIMYCOBACTERIAL  
AGENTS, 807

Piero Sensi  
*University of Milan*  
*Milan, Italy*

Giuliana Gialdroni Grassi  
*University of Pavia*  
*Pavia, Italy*

17 ANTIFUNGAL AGENTS, 881

William J. Watkins  
Thomas E. Renau  
*Essential Therapeutics*  
*Mountain View, California*

18 ANTIMALARIAL AGENTS, 919

Dee Ann Casteel  
*Department of Chemistry*  
*Bucknell University*  
*Lewisburg, Pennsylvania*

19 ANTIPROTOZOAL AGENTS,  
1033

David S. Fries  
*TJ Long School of Pharmacy*  
*University of the Pacific*  
*Stockton, California*

Alan H. Fairlamb  
*Division of Biological Chemistry*  
*and Molecular Microbiology*  
*The Wellcome Trust Biocentre*  
*University of Dundee*  
*Dundee, United Kingdom*

20 ANTHELMINTICS, 1089

Robert K. Griffith  
*West Virginia University*  
*School of Pharmacy*  
*Morgantown, West Virginia*

INDEX, 1097